Synapse - Naiyer Rizvi

Results (166)

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus

Journal Article

Riely, G. J.; Kris, M. G.; Zhao, B.; Akhurst, T.; Milton, D. T.; Moore, E.; Tyson, L.; Pao, W.; Rizvi, N. A.; Schwartz, L. H.; more...
Clinical Cancer Research (2007)

Fulltext@MSK | Save

A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy

Journal Article

Riely, G. J.; Gadgeel, S.; Rothman, I.; Saidman, B.; Sabbath, K.; Feit, K.; Kris, M. G.; Rizvi, N. A.
Lung Cancer (2007)

Fulltext@MSK | Save

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer

Journal Article

Milton, D. T.; Riely, G. J.; Azzoli, C. G.; Gomez, J. E.; Heelan, R. T.; Kris, M. G.; Krug, L. M.; Pao, W.; Pizzo, B.; Rizvi, N. A.; more...
Cancer (2007)

Fulltext@MSK | Save

A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer

Journal Article

Azzoli, C. G.; Krug, L. M.; Miller, V. A.; Rizvi, N. A.; Kris, M. G.; Dunne, M.; Farmer, A.; Pizzo, B.; Tyson, L.; Seeger, T.; more...
Journal of Thoracic Oncology (2007)

Fulltext@MSK | Save

Phase I/II study of ABI-007 as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)

Meeting Abstract

Rizvi, N. A.; Azzoli, C.; Miller, V.; Ng, K.; Fiore, J.; Chia, G.; Brower, M.; Heelan, R.; Hawkins, M.; Kris, M.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial

Meeting Abstract

Natale, R. B.; Bodkin, D.; Govindan, R.; Sleckman, B.; Rizvi, N.; Capo, A.; Germonpre, P.; Stockman, P.; Kennedy, S.; Ranson, M.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy

Meeting Abstract

Kris, M. G.; Pao, W.; Zakowski, M. F.; Ladanyi, M.; Heelan, R. T.; Schwartz, L.; Zhao, B.; Venkatraman, E.; Rusch, V.; Rizvi, N. A.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Lung cancer: Computerized quantification of tumor response - Initial results

Journal Article

Zhao, B.; Schwartz, L. H.; Moskowitz, C. S.; Ginsberg, M. S.; Rizvi, N. A.; Kris, M. G.
Radiology (2006)

Fulltext@MSK | Save

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib